 Deamino-8-D-arginine vasopressin DDAVP, a synthetic analogue of vasopressin, is a commonly used hemostatic agent to treat uremic bleeding by inducing the release of von Willebrand factor vWF and factor VIII from their storage sites in endothelial cells.Previous studies have shown that one dose of 0.3-0.4μgkg body weight DDAVP infusion for dialysis patients could normalize bleeding time BT, and prevent surgical and renal biopsy bleeding. Nevertheless, two recent studies showed divergent liver biopsy-related bleeding complication rates 0 and 6, respectively in dialysis CHC patients pre-treated with DDAVP. Since most studies evaluating the safety of PLB in CHC patients with dialysis were small and retrospective in nature, and not controlled by the biopsy route, the type of biopsy needle, the use of ultrasound guidance, or the number of passes,further studies are urgently needed to solve this important issue. Thus, we aimed to conducted a large clinical trial to compare the safety profiles of PLB between CHC patients with hemodialysis HD who were pretreated with DDAVP and those with NRF by the same biopsy technique. 